EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S, He Y, Jiang T, Ren S, Zhou F, Zhao C, Li X, Zhang J, Su C, Chen X, Cai W, Gao G, Li W, Wu F, Li J, Zhao J, Hu Q, Zhao M, Zhou C, Hirsch FR.
Liu S, et al. Among authors: li j, li w, li x.
Lung Cancer. 2018 Jun;120:82-87. doi: 10.1016/j.lungcan.2018.04.004. Epub 2018 Apr 4.
Lung Cancer. 2018.
PMID: 29748021